New cocktail targets HER2-Positive bile duct cancer in small trial

NCT ID NCT06178445

Ongoing Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participants and aims to see how many respond to the treatment within 6 months. It is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, cisplatin, trastuzumab, and pembrolizumab
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with HER2-positive biliary tract cancer, potentially improving response rates and survival.
What could go wrong: This is a small, early-phase (phase 2) trial with only 24 participants, so results may not apply to everyone. Combining multiple drugs also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cholangiocarcinoma gallbladder cancer gallbladder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER HER2 HER2 GENE MUTATION

Contacts and locations

Locations

Charité Universitätsmedizin

Berlin, Germany
Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

Hamburg, Germany
Krankenhaus Nordwest (KHNW)

Frankfurt, Germany
LMU München

München, Germany
Medizinische Hochschule Hannover

Hanover, Germany
Universitätsklinikum Augsburg

Augsburg, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, Germany
Universitätsklinikum Göttingen

Göttingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.